Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Change From Baseline in A1C at Week 24 - Saxagliptin 5 mg QPM

Mean change from baseline in A1C at Week 24, adjusted for baseline value.

Time frame: Baseline, Week 24

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Mean change from baseline in FPG at Week 24, adjusted for baseline value.

Time frame: Baseline, Week 24

Percentage of Participants Achieving A1C < 7% at Week 24

Percentage of participants achieving A1C \< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin versus placebo at Week 24.

Time frame: Week 24

Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24

Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.

Time frame: Baseline, Week 24